Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies

Objective Response Rate (ORR) - Arm 1 and Arm 2 Expansion Cohorts

时间窗: Through study completion, an average of 1 year

Anti-tumor activity in subjects treated with TTX-030 as single agent or in combination with specified regimens

Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

时间窗: 1 cycle (each cycle is 21-28 days)

A DLT was defined as any clinically significant AE that occurred during Treatment Cycle 1 that the Investigator or Sponsor considered as possibly or likely related to TTX-030 as a single agent, or the combination of TTX-030 and other agent(s), and met the following criteria: NCI CTCAE Version 5.0 Grade 5 event, Grade 4 hematological or Grade≥3 non-hematological toxicities, or Grade≥3 irAEs. Laboratory abnormalities that were asymptomatic and deemed not clinically significant were not regarded as DLTs. During Dose Escalation, each dosing cohort was completed through the DLT observation window before escalation was allowed within its arm. In each Safety Lead-in cohort, all participants were closely monitored for the occurrence of DLTs.